CLINICAL_TRIALS
trial_result
· 2018-03-26
Clinical Trial Update: A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria [Phase 4]
Summary
This Phase 4 trial update reports the efficacy and safety of omalizumab through 48 weeks in participants with chronic spontaneous urticaria.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Urticaria | Phase 4 | Status: COMPLETED | Results posted: 2018-03-26